20-Bio-A1 Biomaterials and Biocompatibility · December 2014
Nivaar worked solution (AI-drafted; not reviewed by a licensed engineer)
Paper format: National Exams, December 2014 — 04-Bio-A1 Biomaterials and Biocompatibility. Three hours, open book, any non-communicating calculator. Seven questions of equal value (20 marks each, 100 marks total); five constitute a complete paper and only the first five appearing in the answer book are marked. All seven are solved here, because this set is a study resource rather than an examination script. Every question is qualitative/descriptive (materials selection, surface science, host response) rather than numerical, except Question 7, which asks for an engineering interpretation of a small stress–strain data set — that question therefore quotes and reasons from the given numbers while still answering in flowing prose, as the question itself calls for discussion rather than a computed final answer.
Reference texts (the books an open-book candidate should have on the desk for this subject):
Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.
Implantation of any device follows a broadly conserved sequence. Within seconds of implantation, plasma proteins adsorb onto the material surface (the Vroman effect, in which the initial layer of adsorbed proteins is progressively displaced by higher-affinity proteins), and this adsorbed protein layer — not the bare material — is what circulating and infiltrating cells actually "see" first. Blood–material contact activates the coagulation cascade and platelets, forming a provisional fibrin(ogen)-rich matrix at the implant site. Acute inflammation follows within hours: neutrophils infiltrate, release reactive oxygen species and proteolytic enzymes, and attempt to degrade what they cannot phagocytose. If the material or debris is not cleared within roughly a week, the response transitions to chronic inflammation, dominated by monocyte-derived macrophages that attempt to phagocytose the implant surface; when a smooth particle or feature is larger than a macrophage can engulf (which describes the surface of almost any implanted device), the macrophages undergo "frustrated phagocytosis" and fuse into multinucleated foreign body giant cells (FBGCs) at the material–tissue interface — the hallmark cell of the foreign body reaction. Concurrently, fibroblasts and new capillaries form granulation tissue around the implant, and over subsequent weeks the fibroblasts deposit collagen that matures into a dense, largely avascular fibrous capsule that walls the implant off from surrounding tissue — the typical chronic end-state for a non-degradable, non-integrating biomaterial.
The material plays a role at every stage of this cascade rather than being a passive bystander. Surface chemistry and charge govern which plasma proteins adsorb preferentially and in what conformation, which in turn determines how strongly platelets, neutrophils, and macrophages respond. Surface topography and porosity strongly influence the outcome: a smooth, non-porous surface typically ends in a thin, dense avascular fibrous capsule, whereas an appropriately porous or textured surface can promote vascularized tissue ingrowth into the implant, reducing capsule thickness and, in the case of a porous orthopedic coating (Question 4), enabling true bone ingrowth rather than encapsulation. Degradable materials add a further dimension: their degradation products (e.g. the locally acidic breakdown products of some polyester scaffolds) can themselves provoke or prolong an inflammatory response independent of the intact material's own properties. In short, the general cellular sequence is conserved across implant types, but its intensity, duration, and final outcome (thin capsule vs. thick capsule vs. tissue integration) are all materials-dependent.
Several steps in this cascade are, or can escalate into, genuine immune (as opposed to purely inflammatory/foreign-body) responses. Complement activation is the clearest link: adsorbed plasma proteins and certain material surface chemistries can activate the complement cascade (via the alternative or lectin pathway), generating anaphylatoxins (C3a, C5a) that recruit and activate leukocytes — this is an innate immune mechanism, not merely a coagulation event, and it amplifies the downstream inflammatory/foreign-body cascade described above. The macrophage/foreign-body-giant-cell response itself is an innate cell-mediated immune reaction — macrophages are immune effector cells, and their fusion into FBGCs is functionally an immune attempt (ultimately unsuccessful, for a large implant) to destroy foreign material. Where the implant carries a biologic component — an adsorbed or denatured host protein exposing cryptic epitopes, a xenogeneic or allogeneic tissue-derived scaffold, or (directly relevant to Question 2) genetically engineered/exogenous cells — the adaptive immune system can become involved: antigen-presenting cells process the foreign protein or cell-surface antigens and can prime a T-cell and/or antibody response, potentially leading to graft rejection rather than a purely local foreign-body reaction. Finally, leachable additives, residual monomers, or sterilization by-products can act as haptens, binding host proteins and triggering a Type IV (delayed-type) hypersensitivity reaction in susceptible patients. So the answer is that both innate immune mechanisms (complement activation, macrophage-mediated foreign-body response) are essentially always present to some degree, while adaptive, antigen-specific immune responses become relevant specifically when the implant presents a genuinely foreign biological component or immunogenic leachable, rather than an inert synthetic surface alone.
The skin-substitute construct of Question 2 makes this concrete: because it carries living, genetically modified cells rather than an inert polymer alone, its risk profile includes not just the generic foreign-body/fibrous-capsule sequence described here but a real possibility of an adaptive cell-mediated or antibody rejection response, which is exactly why the cell source's immunogenicity (autologous vs. allogeneic) was flagged as essential information to obtain from the cell biologists in that question.
